Related Experiment Video
Updated: May 2, 2026
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
MicroRNA-mRNA functional pairs for cisplatin resistance in ovarian cancer cells
Mei Liu1, Xin Zhang, Chen-Fei Hu
1Laboratory of Cell and Molecular Biology & State Key Laboratory of Molecular Oncology, Cancer Institute & Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, P. R. China. xningzhi@public.bta.net.cn.
Abstract:
Ovarian cancer is the leading cause of death in women worldwide. Cisplatin is the core of first-line chemotherapy for patients with advanced ovarian cancer. Many patients eventually become resistant to cisplatin, diminishing its therapeutic effect. MicroRNAs (miRNAs) have critical functions in diverse biological processes. Using miRNA profiling and polymerase chain reaction validation, we identified a panel of differentially expressed miRNAs and their potential targets in cisplatin-resistant SKOV3/DDP ovarian cancer cells relative to cisplatin-sensitive SKOV3 parental cells. More specifically, our results revealed significant changes in the expression of 13 of 663 miRNAs analyzed, including 11 that were up-regulated and 2 that were down-regulated in SKOV3/DDP cells with or without cisplatin treatment compared with SKOV3 cells with or without cisplatin treatment. miRNA array and mRNA array data were further analyzed using Ingenuity Pathway Analysis software. Bioinformatics analysis suggests that the genes ANKRD17, SMC1A, SUMO1, GTF2H1, and TP73, which are involved in DNA damage signaling pathways, are potential targets of miRNAs in promoting cisplatin resistance. This study highlights candidate miRNA-mRNA interactions that may contribute to cisplatin resistance in ovarian cancer.
Insights
Researchers identified specific microRNAs (miRNAs) and their gene targets involved in cisplatin resistance in ovarian cancer cells. Understanding these interactions could lead to new strategies to overcome drug resistance in patients.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Ovarian cancer is a leading cause of cancer death in women globally.
- Cisplatin chemotherapy is a primary treatment for advanced ovarian cancer.
- Acquired cisplatin resistance limits treatment efficacy in many patients.
Purpose of the Study:
- To identify differentially expressed microRNAs (miRNAs) in cisplatin-resistant ovarian cancer cells.
- To determine potential miRNA targets involved in cisplatin resistance mechanisms.
- To explore miRNA-mRNA interactions contributing to therapeutic resistance.
Main Methods:
- Utilized miRNA profiling and polymerase chain reaction (PCR) to analyze miRNA expression.
- Compared cisplatin-resistant (SKOV3/DDP) and sensitive (SKOV3) ovarian cancer cell lines.
- Employed bioinformatics and Ingenuity Pathway Analysis (IPA) for data interpretation.
Main Results:
- Identified 13 differentially expressed miRNAs between resistant and sensitive cells.
- Found 11 up-regulated and 2 down-regulated miRNAs in cisplatin-resistant cells.
- Bioinformatics analysis implicated genes ANKRD17, SMC1A, SUMO1, GTF2H1, and TP73 in miRNA-mediated cisplatin resistance.
Conclusions:
- Candidate miRNA-mRNA interactions were highlighted as potential drivers of cisplatin resistance.
- This research provides insights into molecular mechanisms underlying ovarian cancer chemoresistance.
- Findings may inform the development of novel therapeutic strategies to combat cisplatin resistance.
Related Concept Videos
01:22MicroRNAs
01:22MicroRNAs
02:56Treatment Resistant Cancers